Dr. Vered Padler-Karavani received her PhD in biochemistry from Tel Aviv University. She then did her postdoctoral training with Prof. Ajit Varki at The University of California, San Diego (UCSD) and subsequently established The Laboratory for Glycoimmunology at Tel Aviv University The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation, and involves cutting edge technologies within these disciplines. She received several prestigious grants from the European Commission (Marie Curie, Health Consortium, ERC) to investigate various aspects of immunology of carbohydrates. With TRANSLINK health consortium (6 academic institutes, 5 hospitals and 3 companies from Israel, Italy, France, Spain, UK, Sweden, Canada and USA; https://cordis.europa.eu/project/id/603049
), she investigated risk factors of animal-derived heart valve implants, in ~5,000 patients. Her research is currently focused on studying mechanisms of glycan immune recognition and responses in animal models and in humans, in vitro and in vivo. Particularly, the immunological basis of anti-carbohydrate antibodies and their implications on cancer and heart diseases, and on developing novel diagnostics and therapeutics for such diseases.